ACXP ACXP - FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including t

ACXP FDA provides further regulatory guidance to Acurx Pharmaceuticals for the ibezapolstat clinical development program, including the potential for a single-phase 3-trial registration plan and a trial Design to support both treatment and reduction of recurrence of C. Difficile infection Acurx Pharmaceuticals - receives FDA guidance on single phase 3 trial NDA for ibezapolstat in cdi - FDA agrees NDA filing possible for both treatment and recurrence reduction with successful trials - FDA open to pre-nda discussion after single phase 3 trial if efficacy results are robust